AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Assess the Absorption, Distribution, Metabolism and Excretion of AZD7325 After Intravenous and Oral Administration
- First Posted Date
- 2009-07-16
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT00940641
- Locations
- 🇬🇧
Research Site, Alderley Park, United Kingdom
Pharmacodynamic/Pharmacokinetic Interactions Between Oral Roflumilast and Inhaled Formoterol
- First Posted Date
- 2009-07-16
- Last Posted Date
- 2016-12-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT00940329
- Locations
- 🇩🇪
Nycomed, Konstanz, Germany
Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia
- First Posted Date
- 2009-07-15
- Last Posted Date
- 2012-01-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 862
- Registration Number
- NCT00939341
- Locations
- 🇹🇭
Research Site, Pathumthani, Thailand
Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 in Healthy Volunteers
- First Posted Date
- 2009-07-15
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT00940212
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Non-Interventional Study of Zoladex in Endometriosis
Completed
- Conditions
- Endometriosis
- First Posted Date
- 2009-07-14
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 408
- Registration Number
- NCT00938496
- Locations
- 🇨🇳
Research Site, Hangzhou, Zhejiang, China
The Study Will Evaluate the Effect of AZD9164 in Patients With Chronic Obstructive Pulmonary Disease
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2009-07-14
- Last Posted Date
- 2011-08-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 25
- Registration Number
- NCT00939211
- Locations
- 🇸🇪
Research Site, Lund, Sweden
AZD2066 Neuropathic Pain - Mechanical Hypersensitivity
Phase 2
Terminated
- Conditions
- Neuropathic PainMechanical Hypersensitivity
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-07-14
- Last Posted Date
- 2012-09-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 87
- Registration Number
- NCT00939094
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine
Phase 1
Terminated
- Conditions
- CancerSolid TumorsAdvanced Solid Malignancies
- Interventions
- First Posted Date
- 2009-07-13
- Last Posted Date
- 2011-02-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT00937664
- Locations
- 🇯🇵
Research Site, Minami-ku, Fukuoka, Japan
Arimidex Therapy Compliance Electronic Monitoring System
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2012-02-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 104
- Registration Number
- NCT00936442
- Locations
- 🇧🇪
Research Site, Overpelt, Belgium
Cost-effectiveness Study of Symbicort as Maintenance and Reliever Therapy (SMART)
Completed
- Conditions
- Asthma
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT00937066
- Locations
- 🇨🇴
Research Site, Bogota, Colombia